AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the ...

Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a ...

Decision made after reviewing results of interim analysisLONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing the ...

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the ...

Peptide therapeutics have progressed from insulin discovery to GLP-1 class molecules, revolutionizing diabetes treatment and ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

Veeva Systems (NYSE: VEEV) today announced a new environmental monitoring (EM) solution to advance quality control (QC) for ...

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.